About 4TEEN4 Pharmaceuticals
4TEEN4 Pharmaceuticals is a company based in Hennigsdorf (Germany) founded in 2013.. 4TEEN4 Pharmaceuticals has raised $94.37 million across 5 funding rounds from investors including Boditech Med, Brandenburg Capital and Wellington Partners Venture Capital. 4TEEN4 Pharmaceuticals offers products and services including Procizumab. 4TEEN4 Pharmaceuticals operates in a competitive market with competitors including Acticor Biotech, Basking Biosciences, AptaTargets, Infensa and CeleCor Therapeutics, among others.
- Headquarter Hennigsdorf, Germany
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name 4Teen4 Pharmaceuticals Gmbh
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$94.37 M (USD)
in 5 rounds
-
Latest Funding Round
$63.69 M (USD), Series C
Nov 13, 2025
-
Investors
Boditech Med
& 3 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of 4TEEN4 Pharmaceuticals
4TEEN4 Pharmaceuticals offers a comprehensive portfolio of products and services, including Procizumab. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Inhibits cDPP3 to treat cardiogenic shock and restore cardiovascular function.
Unlock access to complete
Unlock access to complete
Funding Insights of 4TEEN4 Pharmaceuticals
4TEEN4 Pharmaceuticals has successfully raised a total of $94.37M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $63.69 million completed in November 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series C — $63.7M
- First Round First Round
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2025 | Amount | Series C - 4TEEN4 Pharmaceuticals | Valuation |
investors |
|
| Feb, 2024 | Amount | Series A - 4TEEN4 Pharmaceuticals | Valuation |
investors |
|
| Dec, 2019 | Amount | Series A - 4TEEN4 Pharmaceuticals | Valuation | Brandenburg Capital |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in 4TEEN4 Pharmaceuticals
4TEEN4 Pharmaceuticals has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Boditech Med, Brandenburg Capital and Wellington Partners Venture Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are directed by Brandenburg Capital toward multiple sectors.
|
Founded Year | Domain | Location | |
|
Investments are made in early-stage healthcare startups.
|
Founded Year | Domain | Location | |
|
Late-stage life sciences investments are managed via VC and PE.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by 4TEEN4 Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - 4TEEN4 Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
4Teen4 Pharmaceuticals Comparisons
Competitors of 4TEEN4 Pharmaceuticals
4TEEN4 Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Acticor Biotech, Basking Biosciences, AptaTargets, Infensa and CeleCor Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Immunotherapeutics are developed for ischemic stroke treatment using monoclonal antibodies.
|
|
| domain | founded_year | HQ Location |
Therapeutics for ischemic stroke treatment are developed.
|
|
| domain | founded_year | HQ Location |
Provider of therapeutic solutions for ischemic diseases
|
|
| domain | founded_year | HQ Location |
Peptide drugs for cardiovascular disorders are developed.
|
|
| domain | founded_year | HQ Location |
POC subcutaneous injectable for myocardial infarction treatment is developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about 4TEEN4 Pharmaceuticals
When was 4TEEN4 Pharmaceuticals founded?
4TEEN4 Pharmaceuticals was founded in 2013 and raised its 1st funding round 5 years after it was founded.
Where is 4TEEN4 Pharmaceuticals located?
4TEEN4 Pharmaceuticals is headquartered in Hennigsdorf, Germany. It is registered at Hennigsdorf, Brandenburg, Germany.
Is 4TEEN4 Pharmaceuticals a funded company?
4TEEN4 Pharmaceuticals is a funded company, having raised a total of $94.37M across 5 funding rounds to date. The company's 1st funding round was a Series A of $7.64M, raised on Jun 01, 2018.
What does 4TEEN4 Pharmaceuticals do?
4TEEN4 Pharmaceuticals was founded in 2013 and is based in Hennigsdorf, Germany. Focus is placed on the pharmaceutical sector, where therapeutics and diagnostics for cardiovascular conditions are created. Procizumab is being advanced as a targeted therapy to block the DPP3 pathway in cases of cardiogenic shock. The Dipeptidyl Peptidase 3 biomarker is employed to detect and categorize patients at elevated risk. Oversight is handled by Managing Director Andreas Bergmann.
Who are the top competitors of 4TEEN4 Pharmaceuticals?
4TEEN4 Pharmaceuticals's top competitors include Acticor Biotech, Basking Biosciences and CeleCor Therapeutics.
What products or services does 4TEEN4 Pharmaceuticals offer?
4TEEN4 Pharmaceuticals offers Procizumab.
Who are 4TEEN4 Pharmaceuticals's investors?
4TEEN4 Pharmaceuticals has 4 investors. Key investors include Boditech Med, Brandenburg Capital, Wellington Partners Venture Capital, and HBM Partners.